Zacks Investment Research upgraded shares of REXAHN PHARMACT (RNN) from NEUTRAL to OUTPERFORM on December 16, 2014, with a target price of $0.80.
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on REXAHN PHARMACT (RNN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment